Foresite funds receive millions of Latigo (LTGO) shares in IPO-linked moves
Foresite Capital funds converted 9,041,328 derivative securities into Latigo Biotherapeutics (LTGO) common shares and bought 140,000 more at $18.00 per share on August 10, 2026, following LTGO's IPO. The funds now indirectly hold 3,414,544 LTGO shares, disclaiming beneficial ownership beyond pecuniary interest.
How this was made
The 30-second read
Why it matters
The filing reveals both a massive conversion of private securities into public shares and a modest insider purchase, indicating confidence but also significant dilution.
Market read
Primary insider filing; modest trading relevance for short‑term traders, broader impact limited to biotech float considerations.
What to watch
Potential future financing needs and lock‑up expirations may further affect share supply.
Background
Latigo Biotherapeutics recently completed its IPO; Form 4 filings disclose insider activity immediately post‑offering.
Ticker impact
Foresite Capital funds, each a 10% owner, converted 9,041,328 derivative securities into common stock and purchased 140,000 shares at $18 per share on Aug 10, 2026.
Potential short-term upward pressure from insider buying, but overall impact limited by large conversion dilution.
The conversion adds millions of shares, diluting existing holders, while the $2.5M purchase signals confidence from large shareholders; market reaction likely muted.
Market effects
Biotech IPO dilution may affect sector valuation benchmarks.
US biotech market sees minor supply‑side increase in float.
Limited to investors tracking early‑stage biotech IPOs.
Counterpoint
The large conversion could pressure the stock lower despite insider buying.
Key entities
- companyLatigo Biotherapeutics, Inc.
Biotech firm that recently IPO'd under ticker LTGO.
- investment_fundForesite Capital Management V, LLC
Affiliated fund holding a 10% stake in Latigo.
